Navigation Links
Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio
Date:9/9/2009

STOCKHOLM, September 9 /PRNewswire/ -- Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

"This is a new initiative from Karolinska Development as part of our overall strategy to maximize value appreciation within our portfolio," stated Conny Bogentoft, CEO of Karolinska Development. "We have an exciting group of technologies in this area and we expect the new corporate structure to both reduce costs and speed up development times. It also offers considerable advantages when seeking exit opportunities. Pergamum will be able to represent several or all of the development projects when discussing sales or licensing opportunities with pharma companies. We are not aware of any other similar situation within the industry," added Dr Bogentoft.

Pergamum's development projects currently cover improved wound healing and reduced scar formation, healing hard-to-heal-wounds, the prevention of bacterial and fungal infections, atopic dermatitis and infected wounds and burns.

Magnus Precht, CEO of Pergamum AB, said, "There is a good balance across the business units and we already have three projects undergoing clinical trials. What makes Pergamum different is that we provide each of our individual businesses with access to technical skills and key competencies in an extremely resource-efficient way. This is something that other companies at similar stages of development simply cannot do. In addition, by focusing on related fields we are able to continually acquire and share specialist knowledge that will benefit development over the long term."

Pergamum CEO Magnus Precht will present Pergamum at the Rodman & Renshaw Annual Global Investment Conference in New York September 9-11, 2009 and will be available for one-on-one meetings with investors and potential partners during the conference.

Pergamum's other two owners are Ostersjostiftelsen (The Foundation for Baltic and East European Studies) and Midroc New Technology.

About Karolinska Development:

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development

AB is a new type of company focused on filling the innovation gap within the pharmaceutical industry. Using a unique, highly cost-effective model Karolinska Development commercializes internationally renowned life science innovations, helping to deliver the medical products of the future.

    For more information please contact:

    Conny Bogentoft, CEO, Karolinska Development AB
    Cell phone +46-70-668-61-43
    info@karolinskadevelopment.com
   http://www.karolinskadevelopment.com

    Magnus Precht, CEO, Pergamum AB
    European mobile phone: +46-73-515-7450
    US cell phone: +1-817-312-7277
    magnus.precht@pergamum.com
   http://www.pergamum.com



'/>"/>
SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Karolinska Institutet Awards Honorary Degree to Feinstein Institute CEO Kevin J. Tracey, MD
2. Karolinska Development Invests in EvoStem Finland Oy
3. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
4. The Feinstein to collaborate with Swedens Karolinska Institute
5. 3 new honorary doctors at Karolinska Institutet
6. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
7. Special Autism Issue Published by the College of Optometrists in Vision Development
8. Cepheid Announces Accelerated Development of Flu A Panel Test
9. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
10. Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine
11. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: